Victory Capital Management Inc. Grows Holdings in ICU Medical, Inc. (NASDAQ:ICUI)

Victory Capital Management Inc. increased its holdings in shares of ICU Medical, Inc. (NASDAQ:ICUI) by 0.5% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 142,535 shares of the medical instruments supplier’s stock after purchasing an additional 687 shares during the period. Victory Capital Management Inc.’s holdings in ICU Medical were worth $25,973,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of ICUI. Hexagon Capital Partners LLC boosted its stake in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 122 shares during the period. Allworth Financial LP lifted its position in ICU Medical by 100.0% during the 3rd quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after acquiring an additional 100 shares during the period. Innealta Capital LLC purchased a new position in shares of ICU Medical in the 2nd quarter valued at approximately $32,000. Venturi Wealth Management LLC grew its stake in shares of ICU Medical by 1,510.0% in the 3rd quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock valued at $59,000 after purchasing an additional 302 shares during the last quarter. Finally, EntryPoint Capital LLC increased its holdings in shares of ICU Medical by 731.5% in the first quarter. EntryPoint Capital LLC now owns 449 shares of the medical instruments supplier’s stock valued at $48,000 after purchasing an additional 395 shares during the period. 96.10% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other ICU Medical news, CEO Vivek Jain sold 12,000 shares of ICU Medical stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $163.46, for a total transaction of $1,961,520.00. Following the completion of the transaction, the chief executive officer now owns 104,593 shares in the company, valued at approximately $17,096,771.78. The trade was a 10.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $163.22, for a total transaction of $408,376.44. Following the completion of the sale, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This trade represents a 16.03 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 38,502 shares of company stock valued at $6,573,496. 6.70% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts have recently commented on ICUI shares. Needham & Company LLC restated a “hold” rating on shares of ICU Medical in a research note on Wednesday, November 13th. KeyCorp lifted their price objective on ICU Medical from $198.00 to $209.00 and gave the company an “overweight” rating in a report on Wednesday, November 13th. Jefferies Financial Group started coverage on ICU Medical in a research note on Monday, October 14th. They set a “hold” rating and a $183.00 target price for the company. Raymond James lifted their price target on ICU Medical from $158.00 to $190.00 and gave the company an “outperform” rating in a research note on Thursday, September 12th. Finally, StockNews.com cut ICU Medical from a “buy” rating to a “hold” rating in a research report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $167.86 on Monday. The firm has a market capitalization of $4.11 billion, a price-to-earnings ratio of -36.73 and a beta of 0.66. The company has a debt-to-equity ratio of 0.75, a current ratio of 2.29 and a quick ratio of 1.08. The business’s 50 day simple moving average is $176.43 and its 200-day simple moving average is $143.31. ICU Medical, Inc. has a 12 month low of $82.82 and a 12 month high of $196.26.

About ICU Medical

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.